The association between the health of the intestines and the human body with Akkermansia muciniphila

Background

In recent years, Akkermansia muciniphila (A. muciniphila) has gained considerable attention as an important gut microbe. In addition to endocrine and nervous system diseases, this bacterium can cause musculoskeletal and respiratory problems and other diseases. Many gastrointestinal diseases are associated with disturbances in the gut microbiota, which modulates host metabolism and immune response. A. muciniphila maintains intestinal barrier integrity, modulates the host's immune response, and improves several metabolic pathways, making this bacterium a key component in the pathogenesis of many diseases.

Aim

The aim of this study was to understand the basic mechanism underlying the relationship between A. muciniphila and diseases and its interactions with hosts, establishing a causal relationship with a therapeutic supplement associated with A. muciniphila.

Results

It is well known that obesity and its related metabolic syndromes, including liver disorders and type 2 diabetes, are a worldwide epidemic that is highly linked to diet. The gut microbiota-diet interaction has been highlighted as a hot research area in treating obesity and other metabolic diseases. One of the "next-generation probiotics" for treating metabolic disorders and the inflammatory responses is A. muciniphila, which has been found to have a crucial role in metabolic diseases.

Conclusion

A. muciniphila has been extensively studied, but little is known about its regulation in type 2 diabetes (T2D). A. muciniphila has been recognized as an important player in body metabolism and offers great promise for treating metabolic disorders associated with obesity and as a future candidate for therapeutic agents.